{"schema_version":"1.0","type":"article","title":"One Less Search for a Vein, a Little More Freedom in Life with Hemophilia","url":"https://drugnews.com.tw/articles/2026-10-03-hemlibra-hemophilia-lasker-2026-en.html","markdown_url":"https://drugnews.com.tw/articles/2026-10-03-hemlibra-hemophilia-lasker-2026-en.md","lang":"en","date":"2026-10-03","publish_at":"2026-10-03T08:00:00+08:00","updated_at":"2026-10-03","category":"商業分析系列","topic":"商業分析系列","tags":["Hemlibra","emicizumab","血友病","Lasker"],"summary":"The 2026 Lasker–DeBakey Clinical Medical Research Award recognizes an invention that changed the treatment of hemophilia A: Hemlibra, a bispecific antibody that can be injected under the skin.","key_points":[],"facts":[],"sections":[],"references":[{"title":"| Research or material","source":"What it supports","date":"","url":""},{"title":"|---|---|---|","source":"","date":"","url":""},{"title":"| Lasker Foundation award page","source":"The three 2026 honorees and the development story","date":"","url":"https://laskerfoundation.org/winners/bispecific-antibody-for-treating-hemophilia-a/"},{"title":"| Chugai award announcement","source":"September 9, 2026 announcement, researchers and award","date":"","url":"https://www.chugai-pharm.co.jp/english/news/detail/20260909210000_1283.html"},{"title":"| Original FIXa/FX bridging study","source":"FVIIIa cofactor mimicry and bridging mechanism; 2012","date":"","url":"https://pubmed.ncbi.nlm.nih.gov/23023498/"},{"title":"| Bispecific antibody engineering paper","source":"Common light chain, charge, purification and formulation; 2013","date":"","url":"https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0057479"},{"title":"| Original HAVEN 1 paper","source":"Randomized comparison in patients with inhibitors; 2017","date":"","url":"https://pubmed.ncbi.nlm.nih.gov/28691557/"},{"title":"| Original HAVEN 3 paper","source":"Comparison in severe disease without inhibitors; 2018","date":"","url":"https://pubmed.ncbi.nlm.nih.gov/30157389/"},{"title":"| US Hemlibra prescribing information","source":"July 2025 revision; dosing, clinical data and warnings","date":"","url":"https://www.gene.com/download/pdf/hemlibra_prescribing.pdf"},{"title":"| EMA product information","source":"Safety, assays and care; accessed September 27, 2026","date":"","url":"https://www.ema.europa.eu/en/documents/product-information/hemlibra-epar-product-information_en.pdf"},{"title":"| TFDA initial approval review","source":"Taiwan’s initial approval on August 28, 2018","date":"","url":"https://www.fda.gov.tw/tc/includes/GetFile.ashx?id=28914&mid=189&t=s"},{"title":"| World Federation of Hemophilia guidelines, third edition","source":"Venous access, prophylaxis and long-term care; 2020","date":"","url":"https://www1.wfh.org/publications/files/pdf-1863.pdf"},{"title":"| NHI reimbursement and payment adjustment notice","source":"Announced February 13, 2026; effective March 1","date":"","url":"https://www.nhi.gov.tw/ch/cp-19659-df117-3258-1.html"},{"title":"| Payment-price adjustment appendix","source":"NT$2,375 to NT$1,728 per milligram; effective March 1, 2026","date":"","url":"https://www.nhi.gov.tw/ch/dl-96560-c47a8b1afd644464bffcf4b8aedbb89f-1.pdf"},{"title":"| March reimbursement comparison table","source":"Removal of additional criteria for severe disease without inhibitors","date":"","url":"https://www.nhi.gov.tw/ch/dl-96562-1f55f63dcab2469ca2fd463a58a3b794-1.pdf"},{"title":"| Fitusiran and section 4.2.7 revision notice","source":"Announced July 15, 2026; effective August 1","date":"","url":"https://www.nhi.gov.tw/ch/cp-20265-d8d60-3258-1.html"},{"title":"| August section 4.2.7 provisions and follow-up form","source":"Initial authorization, four-week hospital visits and concomitant-use reimbursement restriction","date":"","url":"https://www.nhi.gov.tw/ch/dl-100540-8a15198f8cae4fa9935da2227c8950a9-1.pdf"}],"images":[{"alt":"FIXa and its substrate FX associate with the platelet phospholipid surface and are bound by the two Fab ends of one soluble bispecific antibody. The Fc region remains away from the membrane, while a reaction arrow shows FIXa-mediated activation of FX to FXa.","url":"https://drugnews.com.tw/assets/articles/hemlibra-hemophilia-lasker-2026-en/FIG01_EN_R3.png"},{"alt":"Common-light-chain antibody engineering, purification and formulation lead to subcutaneous administration. A four-week weekly loading period is followed by separate weekly, every-two-week and every-four-week maintenance options.","url":"https://drugnews.com.tw/assets/articles/hemlibra-hemophilia-lasker-2026-en/FIG02_EN_R8.png"},{"alt":"Separate trial areas show males aged 12 or older: HAVEN 1 with inhibitors, N=35/18 and ABR 2.9/23.3; HAVEN 3 with severe disease without inhibitors, N=36/35/18 and ABR 1.5/1.3/38.2. Labels identify annualized treated bleeds and the assessment design.","url":"https://drugnews.com.tw/assets/articles/hemlibra-hemophilia-lasker-2026-en/FIG03_EN_R2.png"},{"alt":"A patient receiving subcutaneous prophylaxis is connected without directional arrows to administration, breakthrough bleeding and surgery, aPCC-related risk, testing, joint activity and reimbursement access, together informing long-term product value.","url":"https://drugnews.com.tw/assets/articles/hemlibra-hemophilia-lasker-2026-en/FIG04_EN_v2.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/hemlibra-hemophilia-lasker-2026-en/FIG01_EN_R3.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-10-03）。One Less Search for a Vein, a Little More Freedom in Life with Hemophilia。https://drugnews.com.tw/articles/2026-10-03-hemlibra-hemophilia-lasker-2026-en.html","disclaimer":"This article is intended for industry research and knowledge sharing only. It does not constitute investment, medical, fundraising, or individual stock advice.","translations":{"zh-Hant":"2026-10-03-hemlibra-hemophilia-lasker-2026.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}